34 results about "Membrane Transporters" patented technology

A complex is provided for the treatment of neurogenic conditions having the formula:

where R¹ is

M is a metal ion Ca(II), Mg(II), Cu(II) or Ni(II); n is an integer 1 or 2; R is BBB peptide, transferrin, membrane transporter peptide, TAT peptide, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, L-lactate, L-leucine, L-tryptophan, and L-glutamate; and R is coupled to M through a carboxylate moiety. Magnesium (II) represents the preferred metal ion as magnesium is known to have neuroprotective effects. The metal ion is in part chelated by a non-steroidal anti-inflammatory drug that does not inhibit platelet activity and includes salicylate and ibuprofenate. The complex also includes a ligand operative in transport across the blood brain barrier. A process for making an inventive complex includes the stoichiometric addition of ligands containing carboxylate groups to a solution of the metal ion. In instances where the metal ion is magnesium (II), a stoichiometric ratio of 1:1:1 is found between the non-steroidal anti-inflammatory ligand:magnesium (II):transporter ligand.

The invention discloses a method for constructing an engineering strain for producing flavin mononucleotide, and applications of the engineering strain. According to the method, by using a synthetic biology technology, an intracellular flavinpool component and endometrial secretion are regulated in newly-constructed or existing riboflavin fermenting bacteria, and an inside-cell-membrane-interstitium enzyme catalytic step is novelly added, such that the high-purity flavin mononucleotide is produced through fermentation with microorganisms; and the method specifically comprises: (1) introducinga bifunctional enzyme riboflavin kinase/flavin adenine dinucleotide producing enzyme into riboflavin fermentation bacteria to convert the intracellular flavinpool component from riboflavin to flavin adenine dinucleotide, (2) introducing a flavin adenine dinucleotide internal membrane transporter, and transporting the intracellular flavin adenine dinucleotide into cell membrane interstitium, and (3) introducing 5'-nucleotidase to lyse and convert the flavin adenine dinucleotide in the cell membrane interstitium into the flavin mononucleotide. According to the present invention, under the shaking fermentation condition, the fermentation purity of the flavin mononucleotide (accounting for the total flavin compounds) can be up to 92.4%.

The invention relates to the field of secondary metabolite production in plants and plant cell cultures. More specifically, the invention relates to the use of transporters and more particularly ABC-transporters to enhance the production and/or secretion of secondary metabolites in plants and plant cell cultures.

Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimer's disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis in living cells. The advantage of using trans-membrane antibodies as apoptosis inhibitors is their specific target recognition in the cell and their lower toxicity compared to conventional apoptosis inhibitors. It is shown that a MTS-transport-peptide modified monoclonal anti-caspase-3 antibody reduces actinomycin D-induced apoptosis and cleavage of spectrin in living cells. These results indicate that antibodies conjugated to a membrane transporter peptide have a therapeutic potential to inhibit apoptosis in a variety of diseases.

This invention relates to multi-drug resistance (MDR) in cells, and the use of certain xanthene compounds for determining drug resistance in cells and the effect of test compounds on cell membrane transport by the membrane transporters MDR1, MRP and BCRP. Processes and kits for making these determinations and measuring these effects are described and provided.

The invention relates to a gene capable of regulating and controlling inhibition of vitamin C fermented strain acid production during acid stress and belongs to the technical fields of basic research on vitamin C prepared by fermentation and biological engineering. The key gene for regulating and controlling yield reduction of acid stress induced 2-Keto-L-Gulonic acid (2-KLG) in the production strains is determined, so a metabolic engineering strategy with high pertinence is generated. The expression condition of genes, in particular membrane transport protein genes, of acid-forming bacteria in the vitamin C mixed bacteria fermented system is analyzed by an expression profile chip technology. Compared with ketogenic gulonic acid bacteria subjected to single cultivation, the ketogenic gulonic acid bacteria subjected to mixed bacteria cultivation have 45 upregulated membrane transport protein genes and 15 down regulated membrane transport protein genes. The notable thing is that: 7 iron ion transport protein genes are inhibited to express. After acid stress, the iron ion transport protein genes are over expressed. During fermentation, the iron ions are added to inhibit mixed bacteria to ferment and generate acid. The result shows that the iron ion transport protein exerts reverse action in the process of yield reduction of 2-KLG generated by the acid stress induced mixed bacteria fermentation.

The invention relates to the field of secondary metabolite production in plants and plant cell cultures. More specifically, the invention relates to the use of transporters and more particularly ABC-transporters to enhance the production and/or secretion of secondary metabolites in plants and plant cell cultures.

The invention relates to the multi-drug resistance (MDR) of Lapatinib (formula 1) in reversing tumour cells which are mediated by membrane transport proteins (ABC) families such as P-glycoprotein (P-gp), multi-drug resistance related protein (MRP1), breast cancer multi-drug resistance related proteins (ABCG2 and BCRP) and the like. The Lapatinib is used together with anti-cancer drugs such as anthracyclines, catharanthines, taxols, podophyllotoxins, camptothecins and the like to restore the sensitivity of MDR tumor cells to the anticancer drugs. The Lapatinib is applied to combination chemotherapy of drug-resistant patients in clinical chemotherapy or the prevention of drug-resistance generation for the tumor cells.

Platinum-acridines and analogs thereof as cytotoxic agents for cancer treatment. Also provided methods of using hMATE1 (SLC47A1) as a biomarker to identify tumors that are likely to respond to the agents, and epigenetically sensitizing tumor tissue to anticancer drugs targeting this membrane transporter.

The invention discloses a strain for producing L-proline as well as a construction method and application of the strain. Through screening, the inactivation of the two membrane transporters can improve the yield of the L-proline in the L-proline producing strain. The discovery of the invention can provide new thoughts and targets for technicians in the field to construct the L-proline production strain, that is, not only concern on the transformation of the L-proline synthesis route, but also increase the yield of the strain through inactivation of the membrane transporter, thereby providing reference for constructing the production strain with higher yield of L-proline.

This document provides materials and methods for a membrane transporter assay (e.g., an oscillating stimulus transporter assay (OSTA)). OSTA can be used to obtain temporal readouts of transporter activity and to screen for membrane transporter modulators (e.g., agonists or antagonists).

The invention belongs to the technical field of medicine application, and discloses an application of trametinib in preparing a medicine for reversing multi-medicine resistance of tumors. Trametinib can be used for significantly reversing the multi-medicine resistance of the tumors mediated by membrane transport protein to ensure that the sensitivity of P-glycoprotein high expression cells to anti-cancer medicines can be restored. According to the medicine for reversing the multi-medicine resistance of the tumors, disclosed by the invention, trametinib and the anti-cancer medicines can be combined to ensure that the effects of treating and controlling resistant tumors can be achieved by restoring the sensitivity of resistant cells to the anti-cancer medicines.

The invention discloses an application of a cucumis sativus CsHMGB gene in reducing pesticide residue and relieving pesticide toxicity, and relates to an application of the CsHMGB gene in the field ofagriculture. From the perspective of genetics, pesticides are metabolized in plants, the safety quality of cucumis sativuss is improved, pesticide residues are reduced, and meanwhile the problems ofenvironmental pollution and the like are avoided. The residual quantity of propamocarb in a cucumis sativus strain for silencing CsHMGB is increased, and the residual quantity of propamocarb in a cucumis sativus strain for overexpressing CsHMGB is reduced. Cucumis sativus is interfered by ROS after being threatened by propamocarb, the overexpressed CsHMGB can improve the activity of antioxidant enzymes SOD, POD, CAT and the like, and the ASA-GSH circulation capacity is improved. The overexpressed CsHMGB induces up-regulated expression of a detoxifying gene and some genes of a glutathione family and a membrane transporter ABC family. The CsHMGB can relieve poison of propamocarb through an antioxidant enzyme system.

The present invention relates to a living cell, preferably a host cell, that is phloroglucinol resistant, said host cell being characterized in that it overexpresses a polypeptide selected from (i) transmembrane transporters of the ABC family, in particular transmembrane transporters of the PDR subfamily, (ii) transcription factors which control the expression of the transmembrane transporters of the PDR subfamily, and (iii) transmembrane transporters of the MFS family; preferably a polypeptide selected from SNQ2, STE6, PDR3, AQR1, DTR1, FLR1, QDR1, YHK8 and ATR1; and more preferably the SNQ2 transporter. The present invention also relates to a method for producing a phloroglucinol-resistant recombinant host cell. The present invention also relates to a method for producing phloroglucinol.

The invention discloses application of KU55933 in preparation of drugs for reversing multidrug resistance of tumors, and belongs to the technical field of drug application. According to the invention, KU55933 is found to be capable of remarkably reversing tumor multidrug resistance mediated by membrane transporter for the first time, so that ABCG2 high-expression cells recover sensitivity to anti-cancer drugs. The drugs for reversing the multidrug resistance of the tumors can contain KU55933, anti-cancer medicines, carriers and auxiliary agents, can be prepared into a tablet, a particle, a capsule, an oral liquid or an injection form, and can be used for treating and controlling resistant tumors.

The invention belongs to the technical field of angiosteosis treatment and particularly relates to an application of iron sucrose to preparation of a drug for treating angiosteosis induced by hyperphosphatemia. Hyperphosphatemia causes an oxidative stress injury in a vascular smooth muscle cell to induce phenotypic transformation from the vascular smooth muscle cell into an osteoblast and to finally develop into angiosteosis. In experiments of the invention, it is found that the iron sucrose can interfere with the transmembrane transport of inorganic phosphorus in blood, inhibit the expressionof a phosphorus transmembrane transporter and antagonize the oxidative stress injury induced by the hyperphosphatemia, so as to play a role in treating, relieving or inhibiting the angiosteosis induced by the hyperphosphatemia.